Overview

Zanuburutinib in Relapsed and Refractory iMCD: a Prospective, Single-center, Single-arm Trial

Status:
Recruiting
Trial end date:
2025-01-01
Target enrollment:
Participant gender:
Summary
To explore the effectiveness and safety of Zanuburutinib in relapsed and refractory idiopathic Multicentric Castleman's disease (iMCD) patients.
Phase:
Phase 2
Details
Lead Sponsor:
Peking Union Medical College Hospital
Treatments:
Zanubrutinib